359 related articles for article (PubMed ID: 33071055)
1. Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
Cavalier JF; Spilling CD; Durand T; Camoin L; Canaan S
Eur J Med Chem; 2021 Jan; 209():112908. PubMed ID: 33071055
[TBL] [Abstract][Full Text] [Related]
2. Cyclipostins and cyclophostin analogs inhibit the antigen 85C from
Viljoen A; Richard M; Nguyen PC; Fourquet P; Camoin L; Paudal RR; Gnawali GR; Spilling CD; Cavalier JF; Canaan S; Blaise M; Kremer L
J Biol Chem; 2018 Feb; 293(8):2755-2769. PubMed ID: 29301937
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
4. Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis.
Nguyen PC; Delorme V; Bénarouche A; Guy A; Landry V; Audebert S; Pophillat M; Camoin L; Crauste C; Galano JM; Durand T; Brodin P; Canaan S; Cavalier JF
Bioorg Chem; 2018 Dec; 81():414-424. PubMed ID: 30212765
[TBL] [Abstract][Full Text] [Related]
5. Cyclophostin and Cyclipostins analogues, new promising molecules to treat mycobacterial-related diseases.
Nguyen PC; Madani A; Santucci P; Martin BP; Paudel RR; Delattre S; Herrmann JL; Spilling CD; Kremer L; Canaan S; Cavalier JF
Int J Antimicrob Agents; 2018 Apr; 51(4):651-654. PubMed ID: 29241819
[TBL] [Abstract][Full Text] [Related]
6. Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.
Nguyen PC; Delorme V; Bénarouche A; Martin BP; Paudel R; Gnawali GR; Madani A; Puppo R; Landry V; Kremer L; Brodin P; Spilling CD; Cavalier JF; Canaan S
Sci Rep; 2017 Sep; 7(1):11751. PubMed ID: 28924204
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and Structural Characterization of TesA, a Major Thioesterase Required for Outer-Envelope Lipid Biosynthesis in Mycobacterium tuberculosis.
Nguyen PC; Nguyen VS; Martin BP; Fourquet P; Camoin L; Spilling CD; Cavalier JF; Cambillau C; Canaan S
J Mol Biol; 2018 Dec; 430(24):5120-5136. PubMed ID: 30292819
[TBL] [Abstract][Full Text] [Related]
9. A piperidinol-containing molecule is active against
Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
[No Abstract] [Full Text] [Related]
10. Cyclipostins and Cyclophostin Analogues as Multitarget Inhibitors That Impair Growth of
Madani A; Ridenour JN; Martin BP; Paudel RR; Abdul Basir A; Le Moigne V; Herrmann JL; Audebert S; Camoin L; Kremer L; Spilling CD; Canaan S; Cavalier JF
ACS Infect Dis; 2019 Sep; 5(9):1597-1608. PubMed ID: 31299146
[TBL] [Abstract][Full Text] [Related]
11. Direct capture, inhibition and crystal structure of HsaD (Rv3569c) from M. tuberculosis.
Barelier S; Avellan R; Gnawali GR; Fourquet P; Roig-Zamboni V; Poncin I; Point V; Bourne Y; Audebert S; Camoin L; Spilling CD; Canaan S; Cavalier JF; Sulzenbacher G
FEBS J; 2023 Mar; 290(6):1563-1582. PubMed ID: 36197115
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
Saxena AK; Singh A
Curr Top Med Chem; 2019; 19(5):337-355. PubMed ID: 30806318
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological aspects of mycolic acids: an important target against Mycobacterium tuberculosis.
de Souza MV; Ferreira Mde L; Pinheiro AC; Saraiva MF; de Almeida MV; Valle MS
ScientificWorldJournal; 2008 Jul; 8():720-51. PubMed ID: 18677428
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
15. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
16. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
17. Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in
Raynaud C; Daher W; Johansen MD; Roquet-Banères F; Blaise M; Onajole OK; Kozikowski AP; Herrmann JL; Dziadek J; Gobis K; Kremer L
ACS Infect Dis; 2020 Feb; 6(2):324-337. PubMed ID: 31860799
[TBL] [Abstract][Full Text] [Related]
18. An approach for the rational design of new antituberculosis agents.
Pasqualoto KF; Ferreira EI
Curr Drug Targets; 2001 Dec; 2(4):427-37. PubMed ID: 11732641
[TBL] [Abstract][Full Text] [Related]
19. In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Sohn H; Lee KS; Ko YK; Ryu JW; Woo JC; Koo DW; Shin SJ; Ahn SJ; Shin AR; Song CH; Jo EK; Park JK; Kim HJ
Int J Antimicrob Agents; 2008 Jun; 31(6):567-71. PubMed ID: 18337064
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and kinetic evaluation of cyclophostin and cyclipostins phosphonate analogs as selective and potent inhibitors of microbial lipases.
Point V; Malla RK; Diomande S; Martin BP; Delorme V; Carriere F; Canaan S; Rath NP; Spilling CD; Cavalier JF
J Med Chem; 2012 Nov; 55(22):10204-19. PubMed ID: 23095026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
